Home arrow Corporate arrow Newsroom arrow Latest arrow Neuragen Diabetic Trial: Pain Relief For 70%
Neuragen Diabetic Trial: Pain Relief For 70% Print E-mail

HALIFAX, Nova Scotia, Canada (January 6, 2005) – Origin BioMedicinals Inc. announced today the results of a clinical trial using Neuragen® for relief of pain associated with diabetic peripheral neuropathy (DPN).  Of the 29 patients completing the feedback survey, at least 20 patients (69%) noted improvement in pain, usually within minutes of applying Neuragen® topically.  Of these, 17 patients (59%) noted a remarkable 50-100% improvement in pain.  Efficacy was measured by reduction in pain intensity over the first six hours.  This rate of efficacy is comparable or better than the prescribed pharmaceutical drugs for neuropathic pain, but without any side effects. 

Many patients reported that Neuragen® worked better for them than any other medication.  Reported quality of life benefits during the study also included improved joint flexibility, decreased cramping and improved balance, as well as improvement in sleep, work ability, social life, energy and less depression.  DPN is characterized by numbness, tingling or burning pain in the feet and hands, and can affect 40% of diabetics.
 
Neuragen® consists of a proprietary blend of botanical essential oil compounds, which was developed by two large US chronic pain centers in the early 1990’s.  Origin BioMedicinals’ product is used today by health practitioners across North America for the treatment of DPN, post-shingles pain, fibromyalgia and other chronic nerve pain. Neuragen® is a topical oil that can be used only as needed for these painful conditions.    
 
The trial was conducted by health practitioners in Sacramento, California between May-Sep 2004 in collaboration with DiabetesinControl.com and the Yolo County Peripheral Neuropathy Support Groups.  Origin BioMedicinals Inc. is a biotechnology company with a full line of botanical based health products for treating various conditions.
 
For more information, contact:   

Cellie Chisholm, RNCP, Client Relations Manager:
      (902) 423-5745
      (888) 234-7256 (toll-free)
      This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
      Web site: www.originbiomed.com
 
For further background about Neuragen®, visit: www.neuragen.ca

PDF version


Last Updated ( Tuesday, 29 January 2008 )
 
< Prev   Next >